
HUTCHMED expands cancer drug coverage for 2027
Key points
- HUTCHMED (NASDAQ:HCM) secured expanded Chinese national reimbursement coverage for ELUNATE and ORPATHYS, with changes taking effect January 1, 2027.
- HUTCHMED shares last closed at $14.90 on November 13, gaining 0.34% before the announcement.
- The updated reimbursement agreements expand eligible patient groups for two cancer treatments while maintaining coverage for SULANDA and previously approved indications.
HUTCHMED (NASDAQ:HCM) announced expanded Chinese National Reimbursement Drug List (NRDL) coverage for its cancer treatments ELUNATE and ORPATHYS, with the changes taking effect January 1, 2027.
The updated agreements follow contract renewals with China's National Healthcare Security Administration (NHSA), maintaining reimbursement coverage for ELUNATE, ORPATHYS and SULANDA while adding new treatment indications.
ELUNATE (fruquintinib), combined with sintilimab, gains coverage for locally advanced or metastatic renal cell carcinoma in patients whose disease progressed after VEGFR-targeted therapy and who have not received first-line PD-1 or PD-L1 inhibitors.
ORPATHYS (savolitinib), combined with osimertinib, gains coverage for locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer with MET amplification following progression on EGFR-targeted therapy, while its coverage for MET exon 14 skipping alterations is renewed.
China's basic medical insurance covered approximately 1.33 billion people, representing around 95% of the population at the end of 2025, although reimbursement for Category B medicines can involve patient co-payments depending on location and insurance arrangements.
HUTCHMED markets ELUNATE in China in partnership with Eli Lilly, develops ORPATHYS jointly with AstraZeneca, and retains worldwide rights to SULANDA, which it markets in China.



